Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 15;10:624498. doi: 10.3389/fonc.2020.624498

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Tran, Sullivan, Chan, Yin, Sun, Fang, Dugar, Zhou and Bae-Jump

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

SPR965 inhibited invasion in ovarian cancer cells. SPR965 inhibited cell invasion in the Hey and SKOV3 cells, assessed by transwell assays (A). The Hey and SKOV3 cells were treated with SPR965 for 24 h. VEGF products in the media were assessed by VEGF ELISA assay (B). Western blotting results indicated that SPR965 affected the expression of epithelial-mesenchymal transition (EMT) markers including an increase in Slug in Hey cells and a decrease in Snail in both cell lines (C). SPR965 reduced serum VEGF levels in SPR965-treated KpB mice at the end of treatment (D). Immunohistochemistry results confirmed that SPR965 significantly reduced the expression of VEGF in ovarian tumors of KpB mice (E). *P < 0.05, **P<0.01.